Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Revive Therapeutics (RVV)

Revive Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:TSXV:RVV
DateTimeSourceHeadlineSymbolCompany
29/03/202214:57InvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19TSXV:RVVRevive Therapeutics Ltd
24/02/202213:35InvestorsHub NewsWireHAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical ResearchTSXV:RVVRevive Therapeutics Ltd
16/02/202213:03InvestorsHub NewsWireRevive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver TransplantationTSXV:RVVRevive Therapeutics Ltd
19/01/202213:19InvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19TSXV:RVVRevive Therapeutics Ltd
07/01/202213:05InvestorsHub NewsWireRevive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19TSXV:RVVRevive Therapeutics Ltd
16/11/202113:00InvestorsHub NewsWireRevive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta VariantTSXV:RVVRevive Therapeutics Ltd
22/09/202112:30InvestorsHub NewsWireRevive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETFTSXV:RVVRevive Therapeutics Ltd
21/09/202116:50AllPennyStocks.comETF Inclusion Sends Psychedelic Stock SoaringTSXV:RVVRevive Therapeutics Ltd
15/07/202119:47InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trialfor Bucillamine in COVID-19TSXV:RVVRevive Therapeutics Ltd
17/06/202113:59InvestorsHub NewsWireRevive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of PsychedelicsTSXV:RVVRevive Therapeutics Ltd
08/06/202114:12InvestorsHub NewsWireRevive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in IndiaTSXV:RVVRevive Therapeutics Ltd
17/05/202114:48InvestorsHub NewsWireRevive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film StripTSXV:RVVRevive Therapeutics Ltd
27/04/202114:51InvestorsHub NewsWireRevive Therapeutics Files For FDA Orphan Drug Designation for Psilocybin in Traumatic Brain InjuryTSXV:RVVRevive Therapeutics Ltd
22/04/202113:26InvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....contTSXV:RVVRevive Therapeutics Ltd
19/03/202111:56InvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of ...ContTSXV:RVVRevive Therapeutics Ltd
17/02/202114:53InvestorsHub NewsWireRevive Therapeutics Acquires Unique Psilocybin AssetsTSXV:RVVRevive Therapeutics Ltd
18/01/202114:51InvestorsHub NewsWireHow Combat Sports Are Researching Micro-Dosing Psychedelics To Treat Brain InjuriesTSXV:RVVRevive Therapeutics Ltd
14/01/202113:30InvestorsHub NewsWireRevive Therapeutics Announces Research Collaboration with North Carolina State UniversityTSXV:RVVRevive Therapeutics Ltd
31/12/202013:30InvestorsHub NewsWireDr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 StudyTSXV:RVVRevive Therapeutics Ltd
23/12/202014:57InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for BucillamineTSXV:RVVRevive Therapeutics Ltd
12/11/202014:00InvestorsHub NewsWireRevive Therapeutics Provides Update on Oral Thin Film Product with PsilocybinTSXV:RVVRevive Therapeutics Ltd
20/10/202015:58InvestorsHub NewsWireRevive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic CompoundsTSXV:RVVRevive Therapeutics Ltd
29/09/202014:39InvestorsHub NewsWireRevive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19TSXV:RVVRevive Therapeutics Ltd
21/09/202015:15InvestorsHub NewsWireRevive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics ProgramsTSXV:RVVRevive Therapeutics Ltd
16/09/202014:59InvestorsHub NewsWireRevive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COV...TSXV:RVVRevive Therapeutics Ltd
02/09/202014:24InvestorsHub NewsWireRevive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine UseTSXV:RVVRevive Therapeutics Ltd
05/12/201417:01PR Newswire (Canada)Revive Therapeutics Prices and Files Final Prospectus for Equity FinancingTSXV:RVVRevive Therapeutics Ltd
27/06/201412:00Marketwired CanadaRevive Therapeutics Ltd. Announces Positive Results of REV-001 Phase 2A Proof-Of-Concept StudyTSXV:RVVRevive Therapeutics Ltd
27/06/201412:00MarketwiredRevive Therapeutics Ltd. Announces Positive Results of REV-001 Phase 2A Proof-Of-Concept StudyTSXV:RVVRevive Therapeutics Ltd
05/06/201412:00MarketwiredRevive Therapeutics Ltd. Submits Pre-IND Package to the US FDA for Its Gout Drug Candidate, REV-002TSXV:RVVRevive Therapeutics Ltd
 Showing the most relevant articles for your search:TSXV:RVV